270 related articles for article (PubMed ID: 19711426)
41. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Yanase K; Yoshiji H; Ikenaka Y; Noguchi R; Kitade M; Kaji K; Yoshii J; Namisaki T; Yamazaki M; Asada K; Tsujimoto T; Akahane T; Uemura M; Fukui H
Oncol Rep; 2007 Feb; 17(2):441-6. PubMed ID: 17203185
[TBL] [Abstract][Full Text] [Related]
42. Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.
Wei Y; Yang Q; Zhang Y; Zhao T; Liu X; Zhong J; Ma J; Chen Y; Zhao C; Li J
Oncotarget; 2017 Feb; 8(9):15230-15241. PubMed ID: 28122355
[TBL] [Abstract][Full Text] [Related]
43. The molecular mechanism underlying angiogenesis in hepatocellular carcinoma: the imbalance activation of signaling pathways.
Zhao ZC; Zheng SS; Wan YL; Jia CK; Xie HY
Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):529-36. PubMed ID: 14627514
[TBL] [Abstract][Full Text] [Related]
44. Expression of transforming growth factor-beta1 and transforming growth factor-beta receptors in hepatocellular carcinoma and dysplastic nodules.
Paik SY; Park YN; Kim H; Park C
Mod Pathol; 2003 Jan; 16(1):86-96. PubMed ID: 12527718
[TBL] [Abstract][Full Text] [Related]
45. [Inhibitory effects of ampelopsin on angiogenesis].
Luo GQ; Zeng S; Liu DY
Zhong Yao Cai; 2006 Feb; 29(2):146-50. PubMed ID: 16617784
[TBL] [Abstract][Full Text] [Related]
46. Attenuation of transforming growth factor beta-induced growth inhibition in human hepatocellular carcinoma cell lines by cyclin D1 overexpression.
Jong HS; Lee HS; Kim TY; Im YH; Park JW; Kim NK; Bang YJ
Biochem Biophys Res Commun; 2002 Mar; 292(2):383-9. PubMed ID: 11906173
[TBL] [Abstract][Full Text] [Related]
47. Sirtuin 6 promotes transforming growth factor-β1/H2O2/HOCl-mediated enhancement of hepatocellular carcinoma cell tumorigenicity by suppressing cellular senescence.
Feng XX; Luo J; Liu M; Yan W; Zhou ZZ; Xia YJ; Tu W; Li PY; Feng ZH; Tian DA
Cancer Sci; 2015 May; 106(5):559-66. PubMed ID: 25683165
[TBL] [Abstract][Full Text] [Related]
48. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Hagymási K; Tulassay Z
Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
[TBL] [Abstract][Full Text] [Related]
49. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Liu LP; Ho RL; Chen GG; Lai PB
Clin Cancer Res; 2012 Oct; 18(20):5662-71. PubMed ID: 22929805
[TBL] [Abstract][Full Text] [Related]
50. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
51. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma.
Kim KW; Bae SK; Lee OH; Bae MH; Lee MJ; Park BC
Cancer Res; 1998 Jan; 58(2):348-51. PubMed ID: 9443416
[TBL] [Abstract][Full Text] [Related]
52. TGF-β signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells.
Mu X; Lin S; Yang J; Chen C; Chen Y; Herzig MC; Washburn K; Halff GA; Walter CA; Sun B; Sun LZ
PLoS One; 2013; 8(5):e63436. PubMed ID: 23704908
[TBL] [Abstract][Full Text] [Related]
53. Molecular targeting for treatment of advanced hepatocellular carcinoma.
Song IH
Korean J Hepatol; 2009 Sep; 15(3):299-308. PubMed ID: 19783879
[TBL] [Abstract][Full Text] [Related]
54. Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell.
Liu X; Yang Y; Zhang X; Xu S; He S; Huang W; Roberts MS
J Gastroenterol Hepatol; 2010 Feb; 25(2):420-6. PubMed ID: 19793165
[TBL] [Abstract][Full Text] [Related]
55. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
[TBL] [Abstract][Full Text] [Related]
56. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.
Connolly EC; Saunier EF; Quigley D; Luu MT; De Sapio A; Hann B; Yingling JM; Akhurst RJ
Cancer Res; 2011 Mar; 71(6):2339-49. PubMed ID: 21282335
[TBL] [Abstract][Full Text] [Related]
57. Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma?
Ceballos MP; Parody JP; Alvarez Mde L; Ingaramo PI; Carnovale CE; Carrillo MC
Biochem Pharmacol; 2011 Dec; 82(11):1682-91. PubMed ID: 21843516
[TBL] [Abstract][Full Text] [Related]
58. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium.
Benetti A; Berenzi A; Gambarotti M; Garrafa E; Gelati M; Dessy E; Portolani N; Piardi T; Giulini SM; Caruso A; Invernici G; Parati EA; Nicosia R; Alessandri G
Cancer Res; 2008 Oct; 68(20):8626-34. PubMed ID: 18922939
[TBL] [Abstract][Full Text] [Related]
59. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell.
Zhang Q; Guo W; Di C; Lou M; Li H; Zhao Y
Pol J Pathol; 2017; 68(4):312-317. PubMed ID: 29517201
[TBL] [Abstract][Full Text] [Related]
60. Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma.
Kawai T; Yasuchika K; Ishii T; Katayama H; Yoshitoshi EY; Ogiso S; Kita S; Yasuda K; Fukumitsu K; Mizumoto M; Hatano E; Uemoto S
Clin Cancer Res; 2015 Jul; 21(13):3081-91. PubMed ID: 25820415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
